TW201211257A - Permanent human cell line for influenza virus preparation - Google Patents
Permanent human cell line for influenza virus preparation Download PDFInfo
- Publication number
- TW201211257A TW201211257A TW100129162A TW100129162A TW201211257A TW 201211257 A TW201211257 A TW 201211257A TW 100129162 A TW100129162 A TW 100129162A TW 100129162 A TW100129162 A TW 100129162A TW 201211257 A TW201211257 A TW 201211257A
- Authority
- TW
- Taiwan
- Prior art keywords
- cells
- medium
- influenza virus
- cell
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010037008 | 2010-08-16 | ||
| DE102011050353 | 2011-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201211257A true TW201211257A (en) | 2012-03-16 |
Family
ID=44936126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW100129162A TW201211257A (en) | 2010-08-16 | 2011-08-16 | Permanent human cell line for influenza virus preparation |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20130344569A1 (enExample) |
| EP (1) | EP2606128B1 (enExample) |
| JP (1) | JP5928843B2 (enExample) |
| KR (1) | KR101780257B1 (enExample) |
| CN (1) | CN103168100B (enExample) |
| AU (1) | AU2011307655B2 (enExample) |
| BR (1) | BR112013003766B1 (enExample) |
| CA (1) | CA2808453C (enExample) |
| DE (1) | DE112011102737A5 (enExample) |
| DK (1) | DK2606128T3 (enExample) |
| ES (1) | ES2524894T3 (enExample) |
| IL (1) | IL224728A (enExample) |
| MX (1) | MX337687B (enExample) |
| PL (1) | PL2606128T3 (enExample) |
| PT (1) | PT2606128E (enExample) |
| RU (1) | RU2565546C2 (enExample) |
| SG (1) | SG187863A1 (enExample) |
| TW (1) | TW201211257A (enExample) |
| WO (1) | WO2012041311A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024537896A (ja) | 2021-10-18 | 2024-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 |
| AR127674A1 (es) | 2021-10-18 | 2024-02-21 | Regeneron Pharma | Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios |
| CN121343924A (zh) * | 2024-07-15 | 2026-01-16 | 干细胞转化研究中心有限公司 | 极早期干细胞在流感病毒制备、检测和药物筛选中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US20050170463A1 (en) | 1999-04-15 | 2005-08-04 | Abraham Bout | Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins |
| US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| DE19955558C2 (de) * | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| ES2526170T3 (es) * | 2004-12-23 | 2015-01-07 | Medimmune, Llc | Línea celular MDCK no tumorigénica para propagar virus |
| ES2402061T3 (es) * | 2005-10-17 | 2013-04-26 | Medimmune, Llc | Método de aumento de la replicación del virus influenza |
| DE102005054628A1 (de) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
| AU2007347716B2 (en) * | 2006-09-15 | 2013-06-20 | Medimmune, Llc | MDCK cell lines supporting viral growth to high titers and bioreactor process using the same |
-
2011
- 2011-08-16 JP JP2013524350A patent/JP5928843B2/ja active Active
- 2011-08-16 US US13/816,976 patent/US20130344569A1/en not_active Abandoned
- 2011-08-16 AU AU2011307655A patent/AU2011307655B2/en active Active
- 2011-08-16 EP EP11781731.2A patent/EP2606128B1/de active Active
- 2011-08-16 MX MX2013001772A patent/MX337687B/es active IP Right Grant
- 2011-08-16 BR BR112013003766-0A patent/BR112013003766B1/pt active IP Right Grant
- 2011-08-16 DK DK11781731.2T patent/DK2606128T3/en active
- 2011-08-16 RU RU2013110786/10A patent/RU2565546C2/ru active IP Right Revival
- 2011-08-16 TW TW100129162A patent/TW201211257A/zh unknown
- 2011-08-16 ES ES11781731.2T patent/ES2524894T3/es active Active
- 2011-08-16 WO PCT/DE2011/075194 patent/WO2012041311A1/de not_active Ceased
- 2011-08-16 CA CA2808453A patent/CA2808453C/en active Active
- 2011-08-16 PL PL11781731T patent/PL2606128T3/pl unknown
- 2011-08-16 SG SG2013011499A patent/SG187863A1/en unknown
- 2011-08-16 PT PT117817312T patent/PT2606128E/pt unknown
- 2011-08-16 DE DE112011102737T patent/DE112011102737A5/de not_active Withdrawn
- 2011-08-16 KR KR1020137006640A patent/KR101780257B1/ko active Active
- 2011-08-16 CN CN201180050018.7A patent/CN103168100B/zh active Active
-
2013
- 2013-02-14 IL IL224728A patent/IL224728A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012041311A1 (de) | 2012-04-05 |
| AU2011307655B2 (en) | 2015-12-17 |
| MX2013001772A (es) | 2013-06-03 |
| EP2606128B1 (de) | 2014-09-10 |
| ES2524894T3 (es) | 2014-12-15 |
| CA2808453C (en) | 2020-05-05 |
| CN103168100B (zh) | 2016-04-13 |
| IL224728A (en) | 2016-05-31 |
| CA2808453A1 (en) | 2012-04-05 |
| KR101780257B1 (ko) | 2017-09-21 |
| PL2606128T3 (pl) | 2015-02-27 |
| SG187863A1 (en) | 2013-03-28 |
| EP2606128A1 (de) | 2013-06-26 |
| RU2565546C2 (ru) | 2015-10-20 |
| RU2013110786A (ru) | 2014-09-27 |
| KR20130097191A (ko) | 2013-09-02 |
| BR112013003766B1 (pt) | 2021-08-24 |
| JP5928843B2 (ja) | 2016-06-01 |
| JP2013537543A (ja) | 2013-10-03 |
| BR112013003766A2 (pt) | 2016-05-31 |
| CN103168100A (zh) | 2013-06-19 |
| AU2011307655A1 (en) | 2013-03-21 |
| US20130344569A1 (en) | 2013-12-26 |
| DE112011102737A5 (de) | 2013-06-06 |
| DK2606128T3 (en) | 2014-12-01 |
| MX337687B (es) | 2016-03-15 |
| PT2606128E (pt) | 2014-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kang et al. | Influenza virus-like particles as pandemic vaccines | |
| Lai et al. | Process development for pandemic influenza VLP vaccine production using a baculovirus expression system | |
| WO2017136575A1 (en) | Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites | |
| US20220389391A1 (en) | F-genotype mumps virus attenuated strain and construction method therefor and application thereof | |
| CN104812894B (zh) | 新型mva病毒及其用途 | |
| WO2009009215A2 (en) | Enhancement of glycoprotein incorporation into virus-like particles | |
| CA2604732A1 (en) | Vaccine against pandemic strains of influenza viruses | |
| US11206005B2 (en) | Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof | |
| Prel et al. | Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks | |
| CN103168100B (zh) | 用于制备流感病毒的永久人细胞系 | |
| Yan et al. | Virus-like particles derived from a virulent strain of pest des petits ruminants virus elicit a more vigorous immune response in mice and small ruminants than those from a vaccine strain | |
| CN118894910B (zh) | 一种PRRSV-GP3-GP5-M+PCV2-TBCap重组蛋白、疫苗及应用 | |
| CN108888761A (zh) | 表达h7n9亚型禽流感病毒血凝素蛋白的重组杆状病毒灭活疫苗及其制备方法与应用 | |
| Li et al. | Development and characterization of Rift Valley fever virus-like particles | |
| KR102402971B1 (ko) | 말라리아 원충의 메로조이트 표면 단백질-9을 포함하는 바이러스-유사입자 및 이를 이용한 백신 | |
| KR102568329B1 (ko) | 조류인플루엔자 뉴라미니다아제를 포함하는 바이러스-유사입자 및 이를 이용한 범용 백신 | |
| WO2009132195A1 (en) | Immortal avian cell line and methods of use | |
| Schwarzer et al. | METABOLISM OF AVIAN DESIGNER CELLS DURING INFLUENZA AND MVA PRODUCTION | |
| Frensing et al. | SINGLE-CELL ANALYSIS UNCOVERS A NOVEL INFLUENZA A VIRUS-DERIVED DEFECTIVE INTERFERING PARTICLE FOR ANTIVIRAL THERAPY |